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It is said that in order to know where you are and where you are going necessitates the knowledge 
of where you have come from. I recently had one of those memorable 'once in a lifetime' experiences 
celebrating a 30 year graduation anniversary with cherished friends and colleagues, some of 
whom I had not seen for years. 
It seemed a good starting point for 
this article to attempt and outline 
where Cardiology has arrived since I 
qualified and the exciting tomorrow 
that beckons. Space will limit the 
discussion to 2 major clinical 
problems that face us in our clinical 
practice, mainly Ischaemic Heart 
Disease (IHD) and Congestive 
Cardiac Failure (CCF). This article 
will mainly discuss issues relating to 
IHD leaving the topic of CCF for 
the next issue. 
Thirty years ago our management 
of Acute Myocardial Infarction was 
limited to monitoring patients in the 
Coronary Care Unit (CCU) for a 
couple of days and keeping our fingers 
crossed for the patient's survival 
without too many limitations on his 
or her quality of life. Indeed we did 
manage to salvage some of those who 
had a life-threatening arrhythmia or 
heart failure with the use of a 
defibrillator, pacemaker and/or 
medication that was available at the 
time. The concept of myocardial 
salvage and patient rehabilitation was 
an interesting theoretical topic while 
that of myocardial regeneration was 
considered entirely to be in the realms 
of science fiction. 
The pharmacological advances that 
have made a significant impact since 
those days have been many. ACE 
inhibitors (ACEi) appeared in the 
early 80 's and were the first drug that 
actually improved mortality in CCF 
and now have a role to play in patients 
with IHD. Another group of drugs 
that were very helpful in the treatment 
of IHD were considered absolutely 
contraindicated in the presence of 
CCF yet have emerged to be precisely 
the opposite in the 90's - Seta 
Slockers. These two groups of drugs 
(together with Spironolactone) are 
the only ones that actually improve 
survival in patients with CCF. A 
group of drugs released in the past 
10 years, Angiotensin -2 Receptor 
Slockers (ARSs), seem to have the 
same clinical benefits as their ACEi 
cousins. Other drugs that have made 
a Significant impact in the treatment 
of IHD are Statins and Clopidogrel 
which together with Aspirin, Calcium 
Channel Blockers, Nicorandil and 
Trimetazidine complete the array of 
medication available to us in the 
pharmacological management of 
IHD. 
The development of Percutaneous 
Transluminal Coronary Angioplasty 
(PTCA) towards the end of the 70's 
has been without doubt the greatest 
leap forward in the management of 
IHD since the introduction of 
Coronary Artery Bypass Grafting 
(CAB G) in the mid 60 's. The end of 
the 80's saw the development of intra-
coronary stents which reduced the 
incidence of abrupt closure and 
restenosis of lesions and the 
innovation of drug eluting stents 
(DES) a few years ago has greatly 
reduced the Achilles' heel of coronary 
angioplasty namely that of restenosis. 
Because of the availability of other 
devices that can 'debulk' 
atheromatous plaque such as the 
Rotablator or Cutting tools , the 
procedure is now referred to as 
Percutaneous Coronary Intervention 
(PCI). 
Atheromatous plaque that is likely 
to cause acute problems is referred to 
as 'Vulnerable Plaque' and a number 
of newer devices are available in order 
to try and identify these areas that 
are likely to rupture or dissect and 
lead to an Acute Coronary Syndrome 
(ACS). These include intravascular 
ultrasound that may also be modified 
to identify lipid, calcium and necrotic 
areas inside the plaque. This 'Virtual 
Histology' can assist in delivering 
therapy to specific areas inside a 
diseased coronary artery considered 
to be dangerous. 
The ever increasing role of PCI in 
the management of IHD has changed 
the balance of indications for patients 
such that over the past few years the 
number of patients undergoing this 
procedure has exceeded the number 
of patients referred for CABG. Other 
percutaneous procedures which are 
able to occlude Patent Foramen Ovale 
(PFO) , Atrial Septal Defect (ASD) 
and Ventricular Septal Defect (VSD) , 
dilate stenosed Mitral and Pulmonary 
valves, 'clip' mitral regurgitant leaflets, 
perform a mitral annulpolasty or 
implant an Aortic Valve over a 
diseased one, have reduced the 
number of patients referred for 
conventional surgery. The net effect 
of these developments has resulted in 
a further bonding of Cardiologists 
and Cardiac surgeons sharing the 
interventional care of patients in ways 
hitherto un imagined and there is no 
doubt that this 'team' approach will 
evolve even further in the future. 
The management of Unstable 
Angina (UA) and Acute Myocardial 
Infarction (AMI) has changed 
radically over the past 20 years. 
Recognising that early intervention 
dramatically reduces both morbidity 
and mortality in these conditions has 
established roles for thrombolytic 
therapy and PCI particularly in the 
early hours after the onset of pain in 
AMI. The need for a 24 hour 
availability of an experienced PCI 
team is an essential part of any 
modern and effective health service 
though sadly many countries have 
still not implemented the necessary 
procedures . 
Disease 
There are very few contraindications 
to performing Primary PCI and a recent 
study (The Senior PAMI Trial) has 
shown that PCI remains significantly 
superior to thrombolytic therapy in 
patients up to 80 years of age. 
Serious complications of AMI such 
as Acute Mitral Regurgitation and 
acute Ventricular Septal Defect have 
been reduced with early intervention 
and the high mortality associated with 
their occurrence hits been significantly 
reduced with PCI. Together with 
haemodynamic support (which will 
be discussed in the next issue) prompt 
PCI has also changed the bleak 
outlook for patients in cardiogenic 
shock, which condition carried a 
mortality of greater than 95%. Early 
institution of these measures is 
capable of halving this grim statistic. 
It makes little sense to spend so 
much time, effort and money on 
treating a disease without addressing 
its prevention and maximising the 
outcome of its successful treatment. 
Intra-coronary stents which reduced the 
incidence of abrupt closure 
Health education is essential if any 
impact on the future health and 
healthcare of a nation is to be 
improved. Not only must the 
individual be informed and educated 
about healthcare at an early age but 
this process has to include adults, 
who have a major role in bringing up 
children as well as acting as role 
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models. Governments, be they local 
or national, can help by introducing 
measures that encourage a healthier 
diet and facilitate the possibility of 
unencumbered physical exercise for 
all ages. 
Since the beginning of time we have 
had available a therapy that only 
recently is being accepted as being of 
any significant benefit. There exists 
a four letter word that is almost never 
seen in medical textbooks or articles. 
It seems that the use of this word 
seems somehow unscientific or 
unrealistic and as a result such bland 
expressions as 'emotional support' are 
used. This expression goes nowhere 
near the actual experience of the word 
'love', yet it is a scientific fact that 
those who experience love both on a 
personal level as well as in the 
environment in which they live 
reduces the likelihood of illness and 
prolongs life. It really makes living 
a far more enjoyable experience - it 
is such a great shame it is not available 
on prescription! 8J 
KETE~ is indicated as a once daily 800rng 
(2 tablets), 5 day treatment of acute 
exacerbation of chronic bronchitis (AECB), 
acute sinusitis and tonsillitis/pharyngitis caused 
by G~ A beta streptococd, as an altemative 
when beta lactarn antibiotics are not 
appropriate; and for 7 to 10 day treatment of 
mild or moderate community·acquired 
pneumonia. 
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is contraindicated in patients taking cisapride 
and pimozide and in patients with a history 
of hypersensitivity to telithromycin or any 
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have not been established - In patients with 
severe renal impairment (Creatinine 
clearance <30mllmin) the dose should be 
reduced to 400mg once da ily -
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In patients with congenital prolongation of 
the aT Interval, uncorrected hypokalaemia 
or hypomagnesaemia or clinically significant 
bradycardia and those receiving Class lA 
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such as visual disturbances which may 
reduce the capacity to carry out certain 
tasks such as driving and operating 
machinery. 
MAH: Aventis Pharma S.A.20, Avenue 
Raymond Aron, F-92160 ANTONY, France. 
Prescription only medicine . 
*Clinical cure rates for KETEK® were 86% in AECB, 
ranged from 75-85% in acute bacterial sinusitis, and 
ranged from 88-95% in mild to moderate CAP. 
• Ketek® 
j Minimizes induction of macrolide type (ermB) 
resistance in vitro. 
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